Belen D. F.
- Country
- Spain
- Department
- #40453: Unitat de Recerca de Neurologia
Research Overview
- Efficacy and Safety of Vormatrigine in Adults with Focal Epilepsy Receiving Concomitant Antiseizure Medications: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Long-Term Safety and Tolerability of Staccato Alprazolam in Patients Aged 12 and Older with Stereotypical Prolonged Seizures
- Efficacy and Safety Evaluation of PRAX-628 in Adults with Focal Epilepsy: A Double-Blind, Randomized, Multicenter Trial
Data & Insights
Has run more than one trial at 105 of 152 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the management of prolonged seizure disorders, with particular emphasis on developing therapeutic interventions for both pediatric and adult populations.
- Seizure Episode Management
- Rapid Seizure Termination
- Long-term Seizure Control
Their research extends to evaluating novel therapeutic approaches for stereotypical prolonged seizures in patients aged 12 and above.
Therapeutic Applications
The investigator focuses on advancing treatment options for acute seizure management, exploring innovative delivery methods for anticonvulsant medications.
- Emergency Seizure Treatment
- Novel Drug Delivery Systems
- Rapid-Acting Interventions
Their work encompasses both immediate intervention strategies and long-term therapeutic approaches for seizure control.
Clinical Safety
The investigator conducts comprehensive evaluations of treatment safety profiles in neurological interventions, particularly focusing on long-term therapeutic outcomes.
- Safety Assessment Protocols
- Treatment Tolerability Studies
- Long-term Patient Monitoring
Their research emphasizes the importance of establishing both immediate and sustained safety parameters in seizure management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.